Kiniksa Pharmaceuticals International, plc
KNSA
Classifica tra le azioni
#3001
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Prezzo delle azioni
$78.31
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$6.11B
Variazione (1 giorno)
-2.04%
Variazione (1 anno)
102.67%
Paese
GB
Scambia Kiniksa Pharmaceuticals International, plc (KNSA)
Categoria
Healthcare
EPS per Kiniksa Pharmaceuticals International, plc (KNSA)
EPS al June 2026 TTM: $1.07
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Kiniksa Pharmaceuticals International, plc, l’EPS attuale della società (TTM) è $1.07. Alla fine del 2023, la società aveva un EPS di $0.20 una diminuzione rispetto a rispetto a quello del 2022, che era di $2.64.
Storico EPS per Kiniksa Pharmaceuticals International, plc da 2016 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $1.07 | -278.33% |
| 2024 | $-0.60 | -400.00% |
| 2023 | $0.20 | -92.42% |
| 2022 | $2.64 | -214.78% |
| 2021 | $-2.30 | -11.88% |
| 2020 | $-2.61 | -12.71% |
| 2019 | $-2.99 | -14.33% |
| 2018 | $-3.49 | 74.50% |
| 2017 | $-2.00 | 170.27% |
| 2016 | $-0.74 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $2.41 | 125.23% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.02 | -98.24% |
HK
|
